Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Identifieur interne : 002E49 ( Main/Corpus ); précédent : 002E48; suivant : 002E50Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Auteurs : Christian Pifl ; Oswald Bertel ; Günther Schingnitz ; Oleh HornykiewiczSource :
- Neurochemistry International [ 0197-0186 ] ; 1990.
Abstract
We analyzed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys, with and without parkinsonian symptoms, the regional changes in dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and tyrosine hydroxylase activity (TH). Symptomatic monkeys had wide-spread DA loss in subcortical and cortical regions. However, the magnitude of this MPTP-induced DA reduction was markedly smaller than the DA loss in the caudate nucleus and putamen, where only less than 1% DA remained. No comparable loss of DA was found in the subcortical extrastriatal regions of asymptomatic MPTP monkeys, despite more than 90% DA loss in the striatal nuclei. The most pronounced difference in DA levels between the symptomatic and the asymptomatic group was observed in nucleus accumbens, nucleus of the stria terminalis, ventral tegmental area, globus pallidus and the cingulate gyrus. Levels of DOPAC and TH activity paralleled the behavior of DA. In contrast, the concentration of HVA was reduced in many brain regions of both symptomatic and asymptomatic monkeys. These effects of MPTP on extrastriatal DA levels in the rhesus monkey are compared with DA and HVA changes in the brain of patients with Parkinson's disease, and their possible contributory role for the production, by MPTP, of a permanent parkinsonian condition is discussed.
Url:
DOI: 10.1016/0197-0186(90)90148-M
Links to Exploration step
ISTEX:6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title><author><name sortKey="Pifl, Christian" sort="Pifl, Christian" uniqKey="Pifl C" first="Christian" last="Pifl">Christian Pifl</name><affiliation><mods:affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Bertel, Oswald" sort="Bertel, Oswald" uniqKey="Bertel O" first="Oswald" last="Bertel">Oswald Bertel</name><affiliation><mods:affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Schingnitz, Gunther" sort="Schingnitz, Gunther" uniqKey="Schingnitz G" first="Günther" last="Schingnitz">Günther Schingnitz</name><affiliation><mods:affiliation>Boehringer Ingelheim KG, Department of Pharmacology, Ingelheim, F.R.G.</mods:affiliation></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation><mods:affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/0197-0186(90)90148-M</idno><idno type="url">https://api.istex.fr/document/6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002E49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title><author><name sortKey="Pifl, Christian" sort="Pifl, Christian" uniqKey="Pifl C" first="Christian" last="Pifl">Christian Pifl</name><affiliation><mods:affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Bertel, Oswald" sort="Bertel, Oswald" uniqKey="Bertel O" first="Oswald" last="Bertel">Oswald Bertel</name><affiliation><mods:affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Schingnitz, Gunther" sort="Schingnitz, Gunther" uniqKey="Schingnitz G" first="Günther" last="Schingnitz">Günther Schingnitz</name><affiliation><mods:affiliation>Boehringer Ingelheim KG, Department of Pharmacology, Ingelheim, F.R.G.</mods:affiliation></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation><mods:affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Neurochemistry International</title><title level="j" type="abbrev">NCI</title><idno type="ISSN">0197-0186</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="263">263</biblScope><biblScope unit="page" to="270">270</biblScope></imprint><idno type="ISSN">0197-0186</idno></series><idno type="istex">6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4</idno><idno type="DOI">10.1016/0197-0186(90)90148-M</idno><idno type="PII">0197-0186(90)90148-M</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0197-0186</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We analyzed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys, with and without parkinsonian symptoms, the regional changes in dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and tyrosine hydroxylase activity (TH). Symptomatic monkeys had wide-spread DA loss in subcortical and cortical regions. However, the magnitude of this MPTP-induced DA reduction was markedly smaller than the DA loss in the caudate nucleus and putamen, where only less than 1% DA remained. No comparable loss of DA was found in the subcortical extrastriatal regions of asymptomatic MPTP monkeys, despite more than 90% DA loss in the striatal nuclei. The most pronounced difference in DA levels between the symptomatic and the asymptomatic group was observed in nucleus accumbens, nucleus of the stria terminalis, ventral tegmental area, globus pallidus and the cingulate gyrus. Levels of DOPAC and TH activity paralleled the behavior of DA. In contrast, the concentration of HVA was reduced in many brain regions of both symptomatic and asymptomatic monkeys. These effects of MPTP on extrastriatal DA levels in the rhesus monkey are compared with DA and HVA changes in the brain of patients with Parkinson's disease, and their possible contributory role for the production, by MPTP, of a permanent parkinsonian condition is discussed.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Christian Pifl</name><affiliations><json:string>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</json:string></affiliations></json:item><json:item><name>Oswald Bertel</name><affiliations><json:string>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</json:string></affiliations></json:item><json:item><name>Günther Schingnitz</name><affiliations><json:string>Boehringer Ingelheim KG, Department of Pharmacology, Ingelheim, F.R.G.</json:string></affiliations></json:item><json:item><name>Oleh Hornykiewicz</name><affiliations><json:string>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</json:string></affiliations></json:item></author><language><json:string>eng</json:string></language><abstract>We analyzed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys, with and without parkinsonian symptoms, the regional changes in dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and tyrosine hydroxylase activity (TH). Symptomatic monkeys had wide-spread DA loss in subcortical and cortical regions. However, the magnitude of this MPTP-induced DA reduction was markedly smaller than the DA loss in the caudate nucleus and putamen, where only less than 1% DA remained. No comparable loss of DA was found in the subcortical extrastriatal regions of asymptomatic MPTP monkeys, despite more than 90% DA loss in the striatal nuclei. The most pronounced difference in DA levels between the symptomatic and the asymptomatic group was observed in nucleus accumbens, nucleus of the stria terminalis, ventral tegmental area, globus pallidus and the cingulate gyrus. Levels of DOPAC and TH activity paralleled the behavior of DA. In contrast, the concentration of HVA was reduced in many brain regions of both symptomatic and asymptomatic monkeys. These effects of MPTP on extrastriatal DA levels in the rhesus monkey are compared with DA and HVA changes in the brain of patients with Parkinson's disease, and their possible contributory role for the production, by MPTP, of a permanent parkinsonian condition is discussed.</abstract><qualityIndicators><score>7.4</score><pdfVersion>1.2</pdfVersion><pdfPageSize>526 x 692 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1367</abstractCharCount><pdfWordCount>5990</pdfWordCount><pdfCharCount>33228</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>200</abstractWordCount></qualityIndicators><title>Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title><pii><json:string>0197-0186(90)90148-M</json:string></pii><genre><json:string>research-article</json:string></genre><serie><volume>80</volume><pages><last>4550</last><first>4546</first></pages><genre></genre><language><json:string>unknown</json:string></language><title>Proc. natn. Acad. Sci. U.S.A.</title></serie><host><volume>17</volume><pii><json:string>S0197-0186(00)X0191-X</json:string></pii><pages><last>270</last><first>263</first></pages><issn><json:string>0197-0186</json:string></issn><issue>2</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><title>Neurochemistry International</title><publicationDate>1990</publicationDate></host><categories><wos><json:string>BIOCHEMISTRY & MOLECULAR BIOLOGY</json:string><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>1990</publicationDate><copyrightDate>1990</copyrightDate><doi><json:string>10.1016/0197-0186(90)90148-M</json:string></doi><id>6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4/fulltext/pdf</uri></json:item><json:item><original>true</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4/fulltext/txt</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1990</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title><author><persName><forename type="first">Christian</forename><surname>Pifl</surname></persName><affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</affiliation></author><author><persName><forename type="first">Oswald</forename><surname>Bertel</surname></persName><affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</affiliation></author><author><persName><forename type="first">Günther</forename><surname>Schingnitz</surname></persName><affiliation>Boehringer Ingelheim KG, Department of Pharmacology, Ingelheim, F.R.G.</affiliation></author><author><persName><forename type="first">Oleh</forename><surname>Hornykiewicz</surname></persName><affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</affiliation></author></analytic><monogr><title level="j">Neurochemistry International</title><title level="j" type="abbrev">NCI</title><idno type="pISSN">0197-0186</idno><idno type="PII">S0197-0186(00)X0191-X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990"></date><biblScope unit="volume">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="263">263</biblScope><biblScope unit="page" to="270">270</biblScope></imprint></monogr><idno type="istex">6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4</idno><idno type="DOI">10.1016/0197-0186(90)90148-M</idno><idno type="PII">0197-0186(90)90148-M</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1990</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We analyzed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys, with and without parkinsonian symptoms, the regional changes in dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and tyrosine hydroxylase activity (TH). Symptomatic monkeys had wide-spread DA loss in subcortical and cortical regions. However, the magnitude of this MPTP-induced DA reduction was markedly smaller than the DA loss in the caudate nucleus and putamen, where only less than 1% DA remained. No comparable loss of DA was found in the subcortical extrastriatal regions of asymptomatic MPTP monkeys, despite more than 90% DA loss in the striatal nuclei. The most pronounced difference in DA levels between the symptomatic and the asymptomatic group was observed in nucleus accumbens, nucleus of the stria terminalis, ventral tegmental area, globus pallidus and the cingulate gyrus. Levels of DOPAC and TH activity paralleled the behavior of DA. In contrast, the concentration of HVA was reduced in many brain regions of both symptomatic and asymptomatic monkeys. These effects of MPTP on extrastriatal DA levels in the rhesus monkey are compared with DA and HVA changes in the brain of patients with Parkinson's disease, and their possible contributory role for the production, by MPTP, of a permanent parkinsonian condition is discussed.</p></abstract></profileDesc><revisionDesc><change when="1990-03-12">Registration</change><change when="1990">Published</change></revisionDesc></teiHeader></istex:fulltextTEI></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>NCI</jid><aid>9090148M</aid><ce:pii>0197-0186(90)90148-M</ce:pii><ce:doi>10.1016/0197-0186(90)90148-M</ce:doi><ce:copyright type="unknown" year="1990"></ce:copyright></item-info><head><ce:title>Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</ce:title><ce:dedication>Dedicated to Professor Hermann Blaschko on the occasion of his 90th birthday.</ce:dedication><ce:author-group><ce:author><ce:given-name>Christian</ce:given-name><ce:surname>Pifl</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Oswald</ce:given-name><ce:surname>Bertel</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Günther</ce:given-name><ce:surname>Schingnitz</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Oleh</ce:given-name><ce:surname>Hornykiewicz</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Boehringer Ingelheim KG, Department of Pharmacology, Ingelheim, F.R.G.</ce:textfn></ce:affiliation></ce:author-group><ce:date-received day="5" month="2" year="1990"></ce:date-received><ce:date-accepted day="12" month="3" year="1990"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>We analyzed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys, with and without parkinsonian symptoms, the regional changes in dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and tyrosine hydroxylase activity (TH). Symptomatic monkeys had wide-spread DA loss in subcortical and cortical regions. However, the magnitude of this MPTP-induced DA reduction was markedly smaller than the DA loss in the caudate nucleus and putamen, where only less than 1% DA remained. No comparable loss of DA was found in the subcortical extrastriatal regions of asymptomatic MPTP monkeys, despite more than 90% DA loss in the striatal nuclei. The most pronounced difference in DA levels between the symptomatic and the asymptomatic group was observed in nucleus accumbens, nucleus of the stria terminalis, ventral tegmental area, globus pallidus and the cingulate gyrus. Levels of DOPAC and TH activity paralleled the behavior of DA. In contrast, the concentration of HVA was reduced in many brain regions of both symptomatic and asymptomatic monkeys. These effects of MPTP on extrastriatal DA levels in the rhesus monkey are compared with DA and HVA changes in the brain of patients with Parkinson's disease, and their possible contributory role for the production, by MPTP, of a permanent parkinsonian condition is discussed.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</title></titleInfo><name type="personal"><namePart type="given">Christian</namePart><namePart type="family">Pifl</namePart><affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oswald</namePart><namePart type="family">Bertel</namePart><affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Günther</namePart><namePart type="family">Schingnitz</namePart><affiliation>Boehringer Ingelheim KG, Department of Pharmacology, Ingelheim, F.R.G.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oleh</namePart><namePart type="family">Hornykiewicz</namePart><affiliation>Institute of Biochemical Pharmacology, University of Vienna, Borschkegasse 8A, A-1090 Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1990</dateIssued><dateValid encoding="w3cdtf">1990-03-12</dateValid><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">We analyzed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rhesus monkeys, with and without parkinsonian symptoms, the regional changes in dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and tyrosine hydroxylase activity (TH). Symptomatic monkeys had wide-spread DA loss in subcortical and cortical regions. However, the magnitude of this MPTP-induced DA reduction was markedly smaller than the DA loss in the caudate nucleus and putamen, where only less than 1% DA remained. No comparable loss of DA was found in the subcortical extrastriatal regions of asymptomatic MPTP monkeys, despite more than 90% DA loss in the striatal nuclei. The most pronounced difference in DA levels between the symptomatic and the asymptomatic group was observed in nucleus accumbens, nucleus of the stria terminalis, ventral tegmental area, globus pallidus and the cingulate gyrus. Levels of DOPAC and TH activity paralleled the behavior of DA. In contrast, the concentration of HVA was reduced in many brain regions of both symptomatic and asymptomatic monkeys. These effects of MPTP on extrastriatal DA levels in the rhesus monkey are compared with DA and HVA changes in the brain of patients with Parkinson's disease, and their possible contributory role for the production, by MPTP, of a permanent parkinsonian condition is discussed.</abstract><relatedItem type="host"><titleInfo><title>Neurochemistry International</title></titleInfo><titleInfo type="abbreviated"><title>NCI</title></titleInfo><genre type="Journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">1990</dateIssued></originInfo><identifier type="ISSN">0197-0186</identifier><identifier type="PII">S0197-0186(00)X0191-X</identifier><part><date>1990</date><detail type="volume"><number>17</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="issue pages"><start>129</start><end>371</end></extent><extent unit="pages"><start>263</start><end>270</end></extent></part></relatedItem><identifier type="istex">6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4</identifier><identifier type="DOI">10.1016/0197-0186(90)90148-M</identifier><identifier type="PII">0197-0186(90)90148-M</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">BIOCHEMISTRY & MOLECULAR BIOLOGY</classCode><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002E49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:6039C1DD4B333C12FA9B848F335A6AA7CAFF4EA4
|texte= Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
}}
| This area was generated with Dilib version V0.6.23. |  |